Literature DB >> 11502526

Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.

E J Randinitis1, J R Koup, G Rausch, R Abel, N J Bron, N J Hounslow, A B Vassos, A J Sedman.   

Abstract

As the primary route for elimination of clinafloxacin is renal clearance (CL(R)) of unchanged drug, studies were conducted to determine the pharmacokinetic profile of clinafloxacin following administration to young and elderly subjects, subjects with various degrees of renal function, and subjects requiring dialysis. These were open-label studies in which subjects received single oral clinafloxacin doses. Sixteen young subjects (18 to 35 years old) and 16 elderly subjects (>65 years old) were enrolled in a study comparing pharmacokinetic profiles of clinafloxacin in young and elderly subjects. Twenty subjects having various degrees of renal function were enrolled into one of three groups based on degree of renal function as measured by creatinine clearance (CL(CR)). Twelve subjects with severe renal impairment requiring dialysis enrolled in a third study. Clinafloxacin was generally well tolerated by all subjects. Clinafloxacin pharmacokinetic profiles in elderly subjects were dependent only on age-related decreases in renal function. Clinafloxacin maximum concentrations in plasma, areas under the concentration-time curves, and terminal elimination half-life values increased with decreasing CL(CR) values. Total apparent body clearance of clinafloxacin from the plasma after oral administration (CL(oral)) and CL(R) were dependent on CL(CR) according to the following relationships: CL(oral) = 2.3. CL(CR) + 77 and CL(R) = 1.74. CL(CR). Hemodialysis had no significant effect on clinafloxacin clearance. Based on the relationship between CL(CR) and clinafloxacin CL(oral) and CL(R) values, the clinafloxacin dose should be halved in patients having a CL(CR) of <40 ml/min. Further dose adjustment is not warranted in patients requiring hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502526      PMCID: PMC90689          DOI: 10.1128/AAC.45.9.2536-2542.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.

Authors:  M A Cohen; M D Huband; J W Gage; S L Yoder; G E Roland; S J Gracheck
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

2.  In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Drug dosing in renal insufficiency.

Authors:  R L Talbert
Journal:  J Clin Pharmacol       Date:  1994-02       Impact factor: 3.126

4.  Pharmacokinetics of clinafloxacin after single and multiple doses.

Authors:  E J Randinitis; J I Brodfuehrer; I Eiseman; A B Vassos
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.

Authors:  N J Bron; M B Dorr; T G Mant; C L Webb; A B Vassos
Journal:  J Antimicrob Chemother       Date:  1996-12       Impact factor: 5.790

6.  Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Authors:  M A Cohen; M D Huband
Journal:  Diagn Microbiol Infect Dis       Date:  1999-01       Impact factor: 2.803

7.  Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.

Authors:  M A Cohen; M D Huband; S L Yoder; J W Gage; G E Roland
Journal:  J Antimicrob Chemother       Date:  1998-06       Impact factor: 5.790

Review 8.  Structure-activity and structure-side-effect relationships for the quinolone antibacterials.

Authors:  J M Domagala
Journal:  J Antimicrob Chemother       Date:  1994-04       Impact factor: 5.790

Review 9.  Fluoroquinolone toxicities. An update.

Authors:  P S Lietman
Journal:  Drugs       Date:  1995       Impact factor: 9.546

10.  Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.

Authors:  J H Jorgensen; L M Weigel; M J Ferraro; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  2 in total

1.  Drug interactions with clinafloxacin.

Authors:  E J Randinitis; C W Alvey; J R Koup; G Rausch; R Abel; N J Bron; N J Hounslow; A B Vassos; A J Sedman
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

2.  Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Authors:  Die Cheng; Wei-Ren Xu; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.